 BridgeBio Pharma Inc NASDAQ: BBIO, through its affiliate QED Therapeutics Inc and Helsinn Group, has announced FDA approval for Truseltiq infigratinib under the accelerated approval program for cholangiocarcinoma CCA. The approval covers patients with previously treated locally advanced or metastatic CCA harboring an FGFR2 fusion or rearrangement. 